Eli Lilly and Company (NYSE:LLY)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for LLY
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- RD: $LLY Back to 8ema
- debeers: $AMD/$ARDX/$LLY/$MSFT/$NVDA/$PANW/$VLO-Longs all
- woodman: $VKTX broke out last week, then sideways last few days. Now making a little flag. It is extended from the 50d and 200d with the 50 going to cross above the 200d soon. Shorter term, the 8dEMA has caught up again. It has oral and subq obesity drug cand ...
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE You are kinda the expert around here :)
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE https://i.gifer.com/1VF5.gif
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE More hair than I'd imagine.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE - Am I not using my nose-hair scissors (that I told @bigbartabs about) enough?
- debeers: $AMD $ELF-take the dishes off the shelf be a tasty dish youself $LLY-deserves to take a breath $MSFT $NUE $NVDA $PANW Longs all Liking the ELF a lot as it is the stock that benefits so much from KISS AND MAKE UP
- Henry: $NVO $LLY I knew it was too good to be true. Here comes the lawyers: https://www.dailymail.co.uk/health/article-12952757/Ozempic-Novo-Nordisk-lawsuits-gastroparesis-stomach-paralysis.html
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- woodman: $LLY ath; $NVO weekly ath.
- debeers: $ANF/$CHK-winner winner chicken dinner/$CRM/$CRWD/$LLY/$MSFT/$NVDA/$PANW
- vitoB: @debeers $ANF $CHK $CRM $CRWD $LLY $MSFT $NVDA $PANW ...do you have any stops on $ANF or takin profits?
- Margi1983: @debeers $ANF $CHK $CRM $CRWD $LLY $MSFT $NVDA $PANW I thought $CHK went bankrupt in 2020? Yes they did. But now they are back and buying companies!! I am sure the bag holders from that time are excited about more debt
- woodman: $LLY trying to move out of its consolidation/channel.
- debeers: $CRWD/$HD/$LEN/$LLY/$MSFT/$NVDA/$PANW Notes: $CRWD & $PANW- yes you can have both $LEN-Not only raising its divvie4 but buying back 5B of its own shares $LLY-the king is still the king $MSFT- will overtake aapple as most valuable co, $NVDA- you gotta have 1 semi-have the best Allthe aboved IMO and you shoud make bank on all of them
- pebbles: $LLY Missed this breakout. What other healthcare stocks are looking to pop up?
- Onthemark: @pebbles $LLY $AMGN is making a nice cup and handle formation. $ISRG is breaking out today.
- pebbles: @Onthemark $LLY $AMGN $ISRG Thanks! I’ll start tracking.
- debeers: @Henry $ARDX - i have enough to handle with 1 retailer and $CELH, $CRWD $HD $LEN $LLY and $META $MSFT $NVDA $PANW and @Woodman does ALL of Biotech!
- debeers: $AMZN-insinuating itself into sports and delivery king $ANF-I wanted to stay Fran Fran you da man---which would have been catchy except the mistress of supply management is a gal! $ARDX-How can we thank @Woodman enough for this one? $CROX- No ugly shoe blues on thois one. kids feet make it impractical to invest in pricey stuff for them. You look around and they need new ones. How many of the migrant surge is going to wear expensive shoes???Really? $CRWD- this one or $PANW should be in everyone's poprtfolio IMO $ELF- Leave this dishes on the shelf--be a tasty dish yourself! Economy up? Teens buy more. Economy down? We trade down. $LLY-best of class IMO $NVDA- So here we are, in the beginning of the year---Look over the past 1-3-5 years. Does it pay to vote against Jensen Huang? NO NO it doesn't
- scottrades: Good morning everyone! Looks like a bit of a mixed open across the board. We’re seeing some weakness in tech and stocks like $MBLY down near its IPO debut price. The move comes on weak guidance but it could be a good bounce idea for nimble tra ...
- woodman: $LLY trying to breakout up through high of consolidation level (10/13, call it $630). It's been good run already from the bottom in fairly short order on good volume.
- joelsg1: @woodman $LLY And they're selling their weight loss drug direct to consumer, eliminating middle man like $WW which I'm short.
- woodman: @joelsg1 $LLY $WW - Even Oprah - the queen of WW - is on weight loss drugs ($NVO's I think, but she didn't call me back to confirm which one).
- woodman: $LLY had a nice move yesterday to close back above the 50d. It's moving higher again this morning.
- woodman: $LLY artcle. I have an established LT position in this that I don't intend to sell unless the wheels fall off, which I don't expect. ttps://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-outlook-glp1-weight-loss-drug-growth-2023-12
- Margi1983: @woodman $CLRB Thanks for the update. Long with modest position. You really know your biotech stuff. These others are not really biotech but I am also long $VRTX, $LLY, $NVO, and $PFE in the pharma space
- woodman: @Margi1983 $CLRB $VRTX $LLY $NVO $PFE - I won't hold all my shares through, but I still need to decide how much I will hold through. It's risky for sure. I can't imagine the company would be promoting this data so much into the presentation(s), but crazy stuff happens in BioLand. It could be a disappointment even if "good" or just simply an immediate sell the news. One never knows.
- MongosPawn: $LLY Starter taken
- joelsg1: $GPCR Prelim. results for safety and tolerance great but efficacy not, only 5% weight loss after 8 weeks, so stock plunged. Ouch. But this is a small molecule pill, so they can adjust dosage as stomach acids impact. $LLY had slightly better results after 12 weeks. Stay tuned, but dumped half pos.
- woodman: @joelsg1 $GPCR $LLY - Sorry to hear that, though there could be something to be said for good safety translating into less discontinuation even where efficiacy trails other obesity drugs. I have no position and, FWIW, remain partial towards $VKTX which has obesity and NASH data coming next Q. If data aren't good, will see a similar result.
- Motorman: @joelsg1 $GPCR $LLY Jeffries analyst said best in class should exceed 7%. But at least not pulled like $PFE candidate. Added at 28 to a small position.
- woodman: @Motorman $GPCR $LLY $PFE - $PFE needs an obesity asset. It will acquire someone, I speculate.
- BarryC: Hi Everyone!! Hope EVERYONE had an awesome day yesterday!! IF anyone cares, Im currently #Long: $AMZN, $DKNG, $LLY (CALLS), $NVDA, $TGTX, $TSLA and THE BEAST IS BACK!!! $UPST!!!
- Dig44north: $LLY selling off today, below 50DMA, BB’s tight at 4%, small position
- jwstich: @Dig44north $LLY Have been selling nearly all of $LLY over the last 2 weeks. Not sure when or if to get back in. Need a little research on their pipeline. Weight loss drugs are beginning to show weakness as they receive more use.
- BarryC: $LLY VERY tight... #FWIW
- woodman: @BarryC $LLY #FWIW - I still like it and continue just to hold it. Not intended as a trade for me.
- woodman: $LLY - Zepbound may end up being the biggest selling drug ... ever. Seems a tad exuberant, but we'll see. It's the right market. https://www.cnbc.com/video/2023/11/08/eli-lillys-zepbound-has-a-strong-shot-of-being-the-biggest-drug-of-all-time-guggenheims-fernandez.html
- woodman: $NVO ( $LLY ) - I doubt it will have a meaningful effect on stock price - at least not any time soon even if there's a real case here, as these things take a long time to play out - but NVO has been hit in a product liability case for downplaying drug risks associated with ozempic and wegovy. I haven't seen the details but apparently the suit contends that the defendants have failed to warn users “about the true risks of their weight loss drugs, Wegovy and Ozempic,” including the plaintiff who claims to have suffered serious injury as a result of the marketing of the drugs and her use of Ozempic. Likely additional cases to surface quickly. At this juncture, this won't alter my thinking about these two companies and their cash cows.
- traderbren: @woodman $NVO $LLY - thanks for the post.
- champ: @Motorman...$NVO and $LLY.....
- billyzeke: @woodman $NVO $LLY My wife works in the healthcare industry and I can tell you for a fact that these drugs do have some serious adverse side effects on some people. I'm just surprised it's taken this long for the lawsuits to fly.
- woodman: @billyzeke $NVO $LLY - I was aware of some of the side effects, but certainly not the full array of them or how frequently they occur. I think it would take quite a lot - in terms of both severity and frequency of side effects - for people to stop flocking to these, particularly to lose weight. But, also, we are seeing virtually every month some new study touting another medical benefit attributed to these drugs, whether cardio, kidney, cancer (recently colo-rectal), and so forth.
- billyzeke: @woodman $NVO $LLY You're right, people and doctors aren't going to stop using these drugs as long as they are available because they are extremely effective for diabetes and weight loss. It seems it's the longer term use that is causing some of the issues, only time will tell how this all plays out, but like you said this will probably not have any effect on stock price in the near term.
- woodman: @billyzeke $NVO $LLY And if they do have to come off the weight loss drugs due to side effects or serious health concerns, the weight comes back on. https://www.cnbc.com/2023/12/11/zepbound-patients-on-eli-lilly-drug-regain-weight-after-stopping-it.html
- BarryC: Hi Everyone... Hope ya had a great weekend. IF anyone cares. Im currently #Long: $AMZN, $DKNG, $ETHE, $LLY, $NVDA, $TGTX & $UPST.
- traderbren: $LLY - gap below at 558.43 ....which it may look to close in the coming weeks.
- woodman: @traderbren $LLY - leaking out the botttom. Damn.
- joelsg1: @woodman $LLY Bob Lang had this as one of his 3 stocks to Short this week, before the market opened.
- woodman: @joelsg1 $LLY - Did he provide a mailing address for sending coal for his stocking?
- woodman: @joelsg1 $LLY - I'm going to fill in a sell order then hover over the enter button. That usually gets the selling to ease up or stop.
- BarryC: With the exception of $LLY, most still in the Range... Im sitting tight until I get stopped. Sticking to my plan....
- joelsg1: @woodman $LLY He's on The Street Real Money, does this 3 stocks to short each week, I was surprised by this pick as usually his shorts/puts have more of an established downtrend.
- joelsg1: @joelsg1 $LLY He's a technical options trader. Basis for his short: MACD sell signal, RSI collapse, targeting 100d at $555, cover at $612.
- woodman: @joelsg1 $LLY - my techique of faking the Markets out by putting in a sell order but not hitting the enter button usually works. When the Market thinks I am capitulating, it reverses. It's my pschological revenge on the Market.
- traderbren: @woodman $LLY - yep, normally the case. ;-) we were waiting for your name to cross the tape on the new CNBC redesign and then take a position.
- woodman: @traderbren $LLY :-0
- BarryC: Wow, Didn't see how TIGHT $LLY was until now... Worth Watching for sure!
- BarryC: I bot some Next Week $LLY 605 CALLS... Its got such a wide range so I'll speculate this way.
- woodman: @BarryC $LLY - Looks good here moving along the 50d with narrowed BBs. I'm still holding my large (relative to other holdings) position. I plan to just keep holding unless some significant development were to change my mind.
- BarryC: What are the chances all these squeezes go at the same time...? Im currently #LONG (Via Stock or CALLS): $AMZN, $DKNG, $ETHE, $LLY, $NVDA, $TGTX, $TSLA & $UPST
- woodman: $LLY $NVO $VKTX et al - some evidence of a potential link between GLP-1s and lowered risk of colo-rectal cancer. https://endpts.com/new-research-points-to-potential-link-between-glp-1s-and-lowered-risk-of-colorectal-cancer/
- Onthemark: $LLY in a nice squeeze around the 8, 21, and 50dmas. Long from below and been adding. Looking for a move above 600.
- woodman: @mhuie $ETNB - Nice move off the bottom as it is rapidly moving to test that gap from the drop on 10/10. My sense is that many in the obesity space - and related Diabetes/liver/NASH & cardio spaces - are moving on good industry-wide obesity data ...
- phgruver: Possible bounce play with $PFE. The dividend is $0.41/qtr, which equates to 5.67% at this price. Unless you expect $PFE to totally collapse, this is a pretty good #VALUE entry for a solid income in a long term portfolio. $XLV, in general, is down near lows, although $LLY and $NOV seems to be bucking that trend. (I also own $ABBV and $BMY for income)
- Onthemark: $LLY Lilly pulled back on low volume to the 50d on news of Roche entering the weight loss market, but has since bounced.
- Onthemark: $LLY providing a lower entry above the 50d, in a kind of squeeze.
- woodman: @Onthemark $LLY - I'm still holding this and don't intend to sell unless it really messes the bed.
- traderbren: @woodman $LLY - yep, I'm still long too. The news of the $PFE tab sounds like a good alternative to lose weight with side effects of puking & diarrhea! Yikes. ;-)
- scottrades: $LLY Tight along the 8/21 EMAs
- woodman: $LLY $NVO - both are continuing to move in their rising channels. LLY closer to (actually moving along) its rising support drawn from 3/1/23.
- debeers: $AAPL/$BA/$LLY/$MSFT/$NVDA/$PANW/$RH
- woodman: $LLY - https://www.fiercepharma.com/manufacturing/eli-lilly-takes-manufacturing-push-germany-plans-large-new-plant-reuters
- woodman: $LLY sideways into bottom of channel/rising support at the 50d.
- woodman: $LLY added at 585.
- DavidG: @woodman $LLY NIce base. I bought some Nov 6 and sold 17Nov $620 covered calls @ $4.47 -- for annualized return of 22%. I'm holding this and will continue writing call options against it.
-
scottrades: ...
I really want you to focus on the charts today and look for opportunity as it presents itself, now is the time to be intentional.
$TSLA trying to capture the 50 Day
$GOOGL Above the 50 Day
$AI Added to the ATL Could offer an entry today
$UNH watch ... -
scottrades: ...
In Cryptoland, we're still waiting for the news on the Bitcoin Spot ETFs, which could be approved anytime between now and January. This could be a game-changer for the crypto market, as it would attract more investors and liquidity. We've been very ... - scottrades: $LLY inside day. Support just under the 50 Day
- joelsg1: @woodman $GPCR $joelsg1 Yes and still holding a small pos. $LLY pill coming but can't compare data.
- smentor: @scottrades $LLY What does "inside day' mean?
- woodman: $LLY $NVO, et al. for weight loss - something to watch. Employers, through their employee health care plans, are capping coverage for these meds for weight loss (though apparently not for other conditions, such as diabetes). https://www.beckershospitalreview.com/finance/mayo-clinic-moves-to-limit-weight-loss-drug-coverage-for-employees.html
- phgruver: @smentor $LLY ...not Scott, but.... You will see 2 uses of the term. More broadly, the high is lower than the HOD of the day before, AND the Low of the day is higher than the LOD of the day before. More narrowly, the day's open and close are less/more than that of the open and close of the day before, so that today's candle is engulfed by yesterday's candle. Both are technically correct. Make sense? correction on the lower bound.
- phgruver: @smentor $LLY ...not Scott, but.... You will see 2 uses of the term. More broadly, the high is lower than the HOD of the day before, AND the Low of the day is higher than the LOD of the day before. More narrowly, the day's open and close are less/more than that of the open and close of the day before, so that today's candle is engulfed by yesterday's candle. Both are technically correct. Make sense? correction on the lower bound.
- debeers: $AVGO/$CAT/$LLY/$META/$NVDA/$PANW/$RH/$TOL- LONGS ALL
- smentor: @DAN #STOCKS would appreciate your thoughts on $LLY and $NVO
- sgiseller: @smentor $LLY $NVO #STOCKS $BA $ARCB
- woodman: $LLY - A little consolidation around the combined moving averages (50d/20d/8d) with the bottom of its recent rising channel looking like it will catch up to price soon. The recent channel's bottom can be extended to see much longer rising support from March this year (thereafter hitting price in Aug, Oct and Nov).
- traderbren: #Bullish_engulfing - on $NVO & $LLY today
- woodman: @BarryC $NVO - I've been partial to $LLY, but both are walking the same path. I do think $LLY's data is better, but it may not matter much in the end. Funny, NVO has the news today but is up only .3%, whereas LLY is up 2.4% today. I think LLY is positioned a little better on the chart right now in terms of proximity to rising support, which I discussed this morning (though both have a nice, lengthy support line). I plan on holding at least a core position in LLY for a long time unless something very significant fundamentally changes my mind or price just falls apart. I do think both will continue to be winners for some time to come.
- traderbren: $LLY $NVO -- FYI - Pharmaceuticals giant Novo Nordisk ($NVO) says it will invest roughly $6 billion to boost production in Denmark, including for its GLP-1 weight-loss drug, Wegovy. The announcement comes days after the U.S. Food and Drug Administration approved the use of Eli Lilly's ($LLY) GLP-1 as an obesity treatment.
- woodman: @traderbren $LLY $NVO - These two Goliaths in the obesity TA are going at it. Lilly priced Zepbound to undercut Weygovy. Looks like there could be a price war, though the scarcity of the drug (which serves two TAs - obesity and diabetes, with possibly more to come as more testing is done) adds an interesting wrinkle.
- joelsg1: @woodman $GPCR $XBI Missed it but really small spec, $LLY just turned so watching close now.
- woodman: @joelsg1 $GPCR $XBI $LLY - This is a market where, if it's a trade, you have to take your profits on first sign of pullback/stalling/likely pullback. I didn't with this one and am disgusted with myself. I should have just sold it at first sign of pullback like I did with $ETNB. ETNB was a good trade because I didn't F around. First sight of pullback, I was out with a nice gain.
- Motorman: @woodman $GPCR $XBI $LLY $ETNB Your not alone, same mistakes over and over. had a nice gain now flat.
- joelsg1: @woodman $GPCR $XBI $LLY $ETNB Exactly right, I screwed the pooch on this one, never updated my initial stop because pos so small and thought I'd be able to see and react. Thanks for the needed reminder. Although $GPCR is turning a bit.
- woodman: @joelsg1 $GPCR $XBI $LLY $ETNB - It's free to run higher now that I am out.
- scottrades: My notes: $SPY/$QQQ CLOSE THE DOOR! $UUP Back from the dead $TNX Above the 50 $TLT Watch for a higher low $IGV Watch for a PB to the 50 $SMH Backtest time? $GBTC Still in trend $ETHE ETH ETFs Coming $ANET Holding the 8EMA $CRWD Watch the 8EMA $DKNG Watch for an entry $LLY Above the 21 EMA $CCJ Good volume $WFRD At the 50 Day $MSTR looking tired $UBER Microbase $MAR just under the 50 Day $COST Watch for support here.
| Stock Price | $732.20 |
| Change | -1.81% |
| Volume | 2,126,740 |
Eli Lilly and Company is a drug manufacturing company. It discovers, develops, manufactures, and sells products in two business segments: human pharmaceutical products and animal health products.
Request Video of LLYAlready a member? Sign in here.
Past Month
Leading Peers
-
$7.20 53.66%
-
$8.97 21.56%
-
$5.45 16.74%
Past Month
Lagging Peers
-
$8.77 -43.65%
-
$10.27 -20.29%
-
$11.50 -18.59%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!